ClinicaliQ Trial Snapshot
- Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC — Active Not Recruiting • Phase III • NCT03395197.
- Adding talazoparib to enzalutamide delays cancer progression longer than enzalutamide alone in men with advanced prostate cancer.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide. Conditions: mCRPC Interventions: Talazoparib with enzalutamide, Placebo with enzalutamide Lead Sponsor: Pfizer Planned Enrollment: 1054 participants